Compared to the first two drug categories DPP-4i are equally efficacious in lowering HbA1c and have a favorable safety profile with low risk of hypoglycemia due to the incretin-based mechanism of action and neutral effect on body weight. The gene discussed is GCG; the disease is Hypoglycemia.